Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on May 17, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 22,500 shares of its common stock to one new non-executive employee to induce him to accept employment with Vaxart.
加利福尼亞州南舊金山，2024 年 5 月 23 日（GLOBE NEWSWIRE）—— Vaxart, Inc.（納斯達克股票代碼：VXRT）（“公司” 或 “Vaxart”）今天宣佈，董事會薪酬委員會於 2024 年 5 月 17 日向一名新的非執行員工發放了總計 22,500 股普通股的激勵性股權獎勵，以誘使他接受 Vaxart 的工作。
The awards made are as follows: (i) an option to purchase 15,000 shares of Vaxart's common stock, which vests as to 1/4th of the total shares on the one-year anniversary of the grant date of May 17, 2024, and as to 1/48th of the total shares on each month thereafter, and has a per share exercise price equal to the closing price of Vaxart's common stock on the grant date; and (ii) a restricted stock unit award covering 7,500 shares of Vaxart's common stock, which vests as to 25% of the shares underlying the award on the first, second, third and fourth anniversary of the grant date of May 17, 2024.
發放的獎勵如下：（i）購買15,000股Vaxart普通股的期權，該期權在2024年5月17日授予之日一週年紀念日歸屬總股數的四分之一，其後每個月的行使價等於Vaxart普通股的收盤價；以及（ii）限制性股票單位獎勵涵蓋Vaxart的7,500股普通股，在第一、第二、三和四週年之際歸屬於該獎勵所依據股份的25％的撥款日期爲2024年5月17日。
The awards were granted under the Vaxart, Inc. 2024 Inducement Award Plan as an employment "inducement award" pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Vaxart (or following a bona fide period of non-employment) as an inducement material to entering into employment with Vaxart.
根據納斯達克上市規則5635（c）（4），這些獎勵是根據Vaxart, Inc.2024年激勵獎勵計劃作爲就業 “激勵獎勵” 發放的。激勵計劃專門用於向以前不是Vaxart員工（或在真正失業一段時間之後）的個人發放股權獎勵，以此作爲在Vaxart工作的激勵材料。
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and to eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
關於 Vaxart
Vaxart是一家臨床階段的生物技術公司，基於其專有的交付平台開發一系列口服重組疫苗。Vaxart疫苗設計爲使用無需冷藏即可儲存和運輸的藥丸接種，並消除了針刺受傷的風險。Vaxart認爲，其專有的藥丸疫苗交付平台適合提供重組疫苗，這使該公司能夠開發當前上市疫苗的口服版本，併爲新適應症設計重組疫苗。Vaxart的開發計劃目前包括旨在預防冠狀病毒、諾如病毒和流感的藥丸疫苗，以及人乳頭瘤病毒（HPV）的治療性疫苗，這是Vaxart的第一個免疫腫瘤學適應症。Vaxart已經提交了廣泛的國內和國際專利申請，涵蓋了其使用腺病毒和TLR3激動劑進行口服疫苗的專有技術和創新。
Contacts
聯繫人
Vaxart Media Relations:
Mark Herr
Vaxart, Inc.
mherr@vaxart.com
(203) 517-8957
Vaxart 媒體關係部：
馬克·赫爾
Vaxart, Inc.
mherr@vaxart.com
(203) 517-8957
Investor Relations:
Andrew Blazier
FINN Partners
IR@vaxart.com
(646) 871-8486
投資者關係：
安德魯·布拉齊爾
FINN 合作伙伴
IR@vaxart.com
(646) 871-8486
Source: Vaxart, Inc.
來源：Vaxart, Inc.
譯文內容由第三人軟體翻譯。